Semax

The most rigorous human data for Semax is in acute ischemic stroke treatment. Multiple Russian clinical trials, including randomized controlled designs led by Gusev et al., demonstrated that Semax administered intranasally within 6-12 hours of stroke onset improved neurological recovery compared to standard care: improved NIHSS scores (neurological deficit scale), Barthel Index (functional independence), and modified Rankin Scale (disability level). A 2018 study of 110 patients showed plasma BDNF elevation in Semax-treated patients correlating with rehabilitation outcomes. A 2018 fMRI study (n=24 healthy volunteers) documented increased default mode network activity — relevant to the connectivity changes seen in stroke recovery. These are the most clinically significant findings for Semax, derived from appropriate clinical endpoints in relevant patient populations. Grade B (Russian multicenter trials; appropriate endpoints; development institution provenance; not independently replicated outside Russia).

The human cognitive enhancement evidence is substantially weaker than the stroke data. The most frequently cited study is a 1996 Russian [6] investigation in 11 healthy subjects showing 250-1,000 mcg improved attention and short-term memory (71% vs 41% follow-up memory test performance vs baseline). Eleven subjects. In 1996. From the development institution. This is the cornerstone of the 'nootropic evidence' that an enormous community has built on. It is real data. It is also among the thinnest human evidence bases for any widely used compound. Animal models consistently show improved performance on maze-based learning tasks, conditioned avoidance, and memory consolidation under stress, providing the mechanistic support for the cognitive claims. The community experience — consistent reports of improved focus, faster mental processing, clearer working memory — is coherent with the BDNF mechanism and is the strongest category E evidence in this book. Grade C-D for cognitive enhancement: mechanistically compelling, small human study, animal model support, strong community consensus.

Semax has been used clinically in Russia for optic nerve atrophy and optic neuritis — conditions where neurodegeneration in the optic nerve pathway causes visual loss. Russian clinical data documents improved visual function metrics (visual acuity, visual field) in these patients. The BDNF mechanism is coherent: BDNF is a survival factor for retinal ganglion cells and the optic nerve. This is a genuinely distinct clinical application from the stroke literature and represents Semax's breadth as a neuroprotective compound. Grade B (Russian clinical data; optic nerve indications included in Russian registration; not replicated independently).

Beyond acute stroke, Semax is used in Russian clinical practice for cognitive rehabilitation — helping patients recover cognitive function after stroke or traumatic brain injury. The combination of BDNF upregulation, dopaminergic activation, and anti-inflammatory effects provides multiple mechanisms relevant to post-injury cognitive recovery. The 110-patient study showing BDNF-rehabilitation correlation is relevant here. Grade B (clinical use; Russian data; coherent mechanism).

The 2024 study by Inozemtseva [8] et al. (European Journal of Neuropharmacology) found that Semax produced antidepressant-like effects in multiple rodent chronic unpredictable stress models, with efficacy comparable to the PGP tripeptide fragment alone. This is consistent with Semax's serotonergic activation and BDNF upregulation — both implicated in antidepressant mechanism. The community uses Semax for mood and stress resilience support, which is coherent with the preclinical data. Grade C-D (animal model; independent 2024 study; not a primary clinical indication).

The 1996 attention study and the dopaminergic activation mechanism both suggest Semax may support attention function relevant to ADHD-like presentations. Some Russian clinicians have used it off-label for this application. No controlled ADHD trial exists. Grade D (mechanistic + small human study; not clinically validated for ADHD).

Semax is a synthetic heptapeptide: methionine-glutamic acid-histidine-phenylalanine-proline-glycine-proline (MEHFPGP). Molecular weight approximately 815 Da. CAS: 80714-61-0. The N-terminal four residues (MEHF) correspond to ACTH residues 4-7 — the portion of ACTH identified as carrying the CNS nootropic and neuroprotective activity. Residues 4-10 of ACTH constitute the full fragment commonly referenced; Semax uses 4-7 as its core. The C-terminal Pro-Gly-Pro extension resists peptidase cleavage and extends biological half-life from seconds (native ACTH fragments) to approximately 20-30 minutes in plasma. This extension is not pharmacologically passive — PMC11498467 confirmed that PGP alone activates neurotrophin transcription in ischemic tissue, meaning the stability tail contributes directly to Semax's neuroprotective profile.

• Standard Semax (MEHFPGP, ~815 Da): the form studied in all published clinical and preclinical research. Russian commercial formulations: 0.1% nasal drops (100 mcg per 0.1 mL drop) for cognitive and nootropic use; 1% nasal drops (1,000 mcg per 0.1 mL drop) for clinical stroke protocols. The compound in all referenced trials. COA mass spec should confirm ~815 Da.
• N-Acetyl Semax (~857 Da): acetylated at the N-terminus. Community claims: improved stability, improved bioavailability, extended duration of action (6-12 hours vs 2-4 hours for standard Semax). No published head-to-head pharmacokinetic comparison exists. The claimed 30-40% lower effective dose for NA-Semax vs standard Semax is community-derived and not validated in any study. The receptor binding profile may differ from standard Semax. These are not confirmed equivalents — vendors who present them as such are extrapolating.
• N-Acetyl Semax Amidate: further modified with C-terminal amidation. The most modified form; also the most thinly evidenced. The combination of N-acetylation and C-terminal amidation is claimed to produce maximum stability and bioavailability. No published comparative data. The further you move from the original MEHFPGP sequence, the further you move from the clinical evidence base.

FORMS CLARITY

The clinical evidence for Semax — stroke, cognitive rehabilitation, optic nerve protection — was generated with standard Semax (MEHFPGP). N-Acetyl Semax and N-Acetyl Semax Amidate are community-modified variants without independent clinical validation. They may be superior, equivalent, or inferior for specific applications. The answer is not known because the studies do not exist. Users who choose modified forms should understand they are moving further from the evidence base, not closer to it.

Lyophilized Semax is stable for 18-24 months at -20C. Reconstituted for intranasal use, refrigerate at 2-8C and use within 30 days. Solution is clear and colorless. Mass spectrometry confirming ~815 Da (for standard Semax) is the identity verification. Semax is sensitive to heat — do not leave reconstituted product at room temperature for extended periods. Store in amber glass to protect from UV. Oral administration is not viable — GI proteolysis destroys it. The intranasal route is not a preference, it is a pharmacological requirement for CNS delivery.

The most extensively documented and most independently replicated mechanism is rapid BDNF and NGF upregulation in the hippocampus and cortex. The landmark dataset comes from Dolotov et al. (Brain Research, 2006 [1], PMID 16996037): a single intranasal dose of Semax at 50 mcg/kg in rats produced a 3-fold increase in BDNF mRNA and a 1.4-fold increase in BDNF protein in the hippocampus, with a concurrent 1.6-fold increase in TrkB receptor phosphorylation (the downstream signaling step confirming the BDNF was biologically active, not just transcribed). NGF was similarly upregulated. These changes were observed within hours and represented a robust, rapid neurotrophic response to a single dose. BDNF is the primary growth factor supporting neuron survival, synaptic plasticity, learning, and memory consolidation. Its upregulation is mechanistically coherent with every cognitive and neuroprotective application attributed to Semax. The Dolotov finding has been replicated across multiple subsequent animal studies and is consistent with Semax's clinical effects in stroke recovery (where a 2018 trial of 110 post-stroke patients showed plasma BDNF elevation correlating with improved rehabilitation trajectory). Grade C (animal model replicated by multiple groups; human BDNF correlation in stroke patients adds clinical relevance).

A critical mechanistic finding from PMC11498467 (2024 [4], independent group): the Pro-Gly-Pro stability tail of Semax is not a passive pharmacological passenger. PGP alone was shown to activate BDNF, NGF, and their receptor (TrkB, TrkC, TrkA) gene transcription in ischemic cortical tissue in a rat stroke model, with effects that partially overlapped and partially complemented the full Semax molecule. This means Semax delivers two active pharmacological components in one molecule: the ACTH(4-7) core driving cognitive and neurotrophic effects, and the PGP tail contributing independent neuroprotective gene expression. The combined molecule may have additive or synergistic effects in ischemic tissue that neither fragment alone produces. Grade C (independent replication; published 2024; mechanistically specific).

Eremin et al. (2005) [3] demonstrated that Semax activates both dopaminergic and serotonergic brain systems within 30 minutes of intranasal administration in rats — a rapid onset consistent with community reports of acute cognitive effects. The dopaminergic activation is relevant to focus, motivation, and working memory; the serotonergic activation to mood stability and cognitive flexibility. The transcriptomic study by Kasian (PMID 26847159, the same study cited for Selank) also documented Semax's effects on dopamine and serotonin pathway gene expression. Grade C (animal model; replicated; consistent with clinical outcomes).

The Gusev et al. clinical stroke trials documented that Semax shifted the cytokine balance in stroke patients toward neuroprotection: IL-10 upregulation (anti-inflammatory), IL-8 and CRP reduction (pro-inflammatory markers). This immune modulation in the acute post-stroke window is one of the proposed mechanisms by which Semax improves neurological outcomes — reducing the secondary inflammatory damage that occurs in the hours and days after initial ischemic injury. This is the most human-validated mechanistic finding for Semax, graded B because it comes from clinical trial data with appropriate endpoints, albeit from Russian development institution trials. Grade B (human stroke patients; clinical trial setting; Russian provenance).

Like Selank, Semax has been proposed to inhibit enkephalinase enzymes — extending endogenous enkephalin half-life. Some sources cite this as a shared mechanism explaining both compounds' positive effects on stress resilience and emotional regulation. The evidence for enkephalinase inhibition is better documented for Selank (Kost 2001, Meshavkin 2006) than for Semax specifically. Whether Semax independently inhibits enkephalinase at relevant doses is not definitively established. Grade D (mechanistically plausible; limited direct Semax-specific evidence).

MECHANISM CONFIDENCE RANKING

1. BDNF/NGF upregulation: most independently replicated (Grade C); human BDNF correlation in stroke trial adds weight. 2. PGP fragment neuroprotection: recent independent 2024 data (Grade C). 3. Dopaminergic/serotonergic activation: animal model, replicated (Grade C). 4. Anti-inflammatory cytokine modulation: best human data, stroke-specific (Grade B). 5. Enkephalinase inhibition: thin direct evidence for Semax specifically (Grade D). Unlike Selank, the receptor binding map for Semax's cognitive effects also remains incompletely characterized — the pathway from Semax to BDNF transcription has not been fully resolved.

• Intranasal (primary evidence route): the route used in Russian clinical trials. Olfactory pathway provides efficient CNS delivery. Accurate delivery technique is essential — same as Selank: head slightly back, gentle sniff, olfactory mucosa target. Standard concentration: 0.1% for nootropic use (100 mcg per drop); 1% for clinical stroke protocols (1,000 mcg per drop). Community users work with 0.1% exclusively.
• SubQ injectable: systemic distribution; slower CNS onset than intranasal. Used by some community users. No dedicated Semax injectable clinical trial. Extrapolated from intranasal data. Appropriate when intranasal is not practical.
• Oral: not viable. GI proteolysis destroys Semax before absorption. Not a route.

Semax has a plasma half-life of approximately 20-30 minutes — longer than Selank's 2-5 minutes due to the Pro-Gly-Pro extension's greater resistance to peptidase degradation. After intranasal administration, the olfactory pathway provides rapid direct CNS access with onset of subjective cognitive effects reported within 20-40 minutes. The downstream effects — BDNF transcription, synaptic potentiation, receptor activation — persist for 2-4 hours per dose with standard Semax, and reportedly 6-12 hours with N-Acetyl Semax (community claim; no published PK data). Unlike Selank's nearly immediate GABA-mediated anxiolytic onset, Semax's cognitive effects build over the first 30-60 minutes as neurotrophic and monoaminergic cascades engage. No detailed Western pharmacokinetic study has been published.

The Russian approved formulation is 0.1% solution (1 mg/mL = 100 mcg per 0.1 mL drop) for nootropic/cognitive use and 1% solution (10 mg/mL = 1,000 mcg per 0.1 mL drop) for clinical stroke protocols. Community users reconstruct from lyophilized powder into 0.1% concentration for nootropic use.

Vial Size

BAC Water

Concentration

Per 0.1 mL drop

Notes

5 mg

5.0 mL

1,000 mcg/mL (0.1%)

100 mcg

Standard nootropic concentration — matches Russian 0.1% formulation

5 mg

0.5 mL

10,000 mcg/mL (1%)

1,000 mcg

Clinical stroke concentration — not for community nootropic use

10 mg

10.0 mL

1,000 mcg/mL (0.1%)

100 mcg

Larger vial at nootropic concentration

Intranasal technique: reconstitute, transfer to a metered-dose amber glass nasal spray atomizer. Head slightly back. One spray or 2-3 drops per nostril. Gentle sniff — olfactory mucosa delivery, not throat delivery. Alternate nostrils to reduce cumulative irritation. For Semax specifically, avoid forceful inhalation more than Selank — the stimulatory profile means incorrect delivery that pushes Semax to the throat can cause nasal burning without the CNS effect.

Vial Size

BAC Water

Concentration

1 unit (U-100)

Notes

5 mg

1.0 mL

5,000 mcg/mL

50 mcg

Standard injectable concentration

5 mg

2.0 mL

2,500 mcg/mL

25 mcg

Lower concentration; better dose precision at low volumes

Use Case

Dose

Frequency

Timing

Cycle

Entry-level (first use)

250-400 mcg

Once daily

Morning only

5-7 days; assess response

Standard nootropic

500-900 mcg

1-2x daily

AM + midday; NEVER after 3pm

10-14 days on, 7 days off

Advanced (experienced users)

1,000-1,200 mcg

1-2x daily

AM + midday

10-14 days on, 7 days off

N-Acetyl Semax

300-600 mcg

Once daily

Morning only

10-14 days on, 7 days off

Semax + Selank combination

300-500 mcg Semax + 250-500 mcg Selank

Both daily

Selank AM; Semax midday

10-14 days on, 7 days off

TIMING IS CRITICAL — INSOMNIA IS THE PRIMARY RISK

Semax's dopaminergic activation is the principal source of sleep disruption. Unlike Selank (which has mild psychostimulant quality), Semax has a more pronounced stimulatory effect in some users. Any administration after 2-3pm risks insomnia or delayed sleep onset in sensitive individuals. Morning-only protocols are the safest approach for first-time users. Even experienced users cap dosing at midday. This is the single most important practical note in the entire Semax dosing section.

The Russian stroke protocols — 9,000-18,000 mcg/day via 1% intranasal solution within 6-12 hours of ischemic onset — are cited here for reference only. These protocols are conducted under clinical supervision in acute care settings. They are not appropriate for self-administration. The dose range is 15-30 times above community nootropic use. The indication is a medical emergency. This information is included because community members frequently cite the stroke evidence to justify nootropic use — and the dose gap between these two applications needs to be clearly documented.

No mandatory lab work for standard short nootropic cycles. Users with any history of psychosis or bipolar disorder: dopaminergic activation warrants caution and physician discussion. Users with diabetes or hypertension: Russian clinical guidance notes caution for these populations with Semax. Standard note applies: stop and assess if unexpected psychological effects (heightened anxiety, racing thoughts, irritability) occur at any dose.

Semax has a clean safety profile in published clinical data across decades of Russian use. No serious adverse events have been documented in any published study. The adverse effect profile is predictable and manageable. The most significant practical concern — sleep disruption — is entirely preventable with appropriate timing. Unlike the healing peptides in prior chapters, there are no angiogenic mechanism concerns, no hormonal effects, and no known interactions with organ systems beyond the CNS.

• Insomnia and sleep disruption: the most clinically significant adverse effect. Dopaminergic activation from late-day dosing delays sleep onset and reduces sleep quality. Entirely prevented by dosing before 2pm. In some sensitive users, even morning dosing can affect sleep — reduce dose or discontinue evening Semax use.
• Nasal irritation and dryness: with repeated intranasal use. Similar to Selank. Managed with lower concentration formulations, alternating nostrils, and saline rinse. 1% solution causes more nasal irritation than 0.1% due to higher peptide concentration.
• Headache: occasionally reported at higher doses or during initial use. Typically resolves with dose reduction or discontinuation.
• Transient anxiety or agitation: at higher doses in sensitive individuals. The dopaminergic/serotonergic activation that produces cognitive enhancement can occasionally overshoot into anxious activation. This is the opposite of Selank's profile — important when choosing between them. Dose reduction resolves it; pairing with Selank can prevent it.
• Mild appetite suppression: occasionally reported. Not a primary effect but a consistent secondary finding in some users.

• Pregnancy and breastfeeding: no safety data; avoid.
• Severe psychiatric disorders (schizophrenia, bipolar disorder, psychosis history): dopaminergic activation warrants significant caution. Russian clinical guidance specifically notes these conditions as requiring careful physician oversight.
• Poorly controlled diabetes: Russian clinical prescribing information notes caution in this population.
• Uncontrolled hypertension: same Russian clinical caution.
• Acute infection or fever: no direct contraindication, but immune-modulating effects warrant deferral until recovery.

Semax has a stronger Russian regulatory position than Selank:

• Russia — Vital and Essential Drugs List (since 2011): the highest domestic regulatory designation available. Semax is not merely approved; it is classified as medically indispensable for the Russian healthcare system. Indications: ischemic stroke, TIA, cognitive disorders, optic nerve disease. Available by prescription in Russian and CIS country pharmacies in 0.1% and 1% formulations.
• United States — research chemical, not FDA-approved: FDA Category 2 removal April 22, 2026 (same pattern as BPC-157, Selank, KPV). Semax acetate and free base forms were removed from Category 2 when nominators withdrew nominations. PCAC review July 24, 2026 (Day 2 of PCAC) for cerebral ischemia, migraine, and trigeminal neuralgia — notably neurological indications, distinct from Selank's GAD/anxiety focus. A favorable PCAC recommendation for cerebral ischemia would give Semax the clearest path to compounding pharmacy access of any peptide in this book, given its clinical indication alignment with the Russian evidence base.
• EU: not approved. No EMA registration. No completed EU trials.

WADA STATUS — SAME UNCERTAINTY AS SELANK

Neither Semax nor Selank appears by name on the 2026 WADA Prohibited List. Both face the same S0 ambiguity: WADA's blanket prohibition on non-approved substances does not provide formal guidance on whether Russian Vital and Essential Drugs List status satisfies the S0 exemption criteria. Semax's stronger Russian regulatory status (Vital Medicines List vs mere registration for Selank) might argue more persuasively for S0 exemption — but WADA has not published a formal determination. Athletes subject to testing should verify with their specific anti-doping authority before use. Do not assume either compound is permitted based on absence from the explicit list.

The Semax + Selank combination is built on genuine mechanistic complementarity: Semax provides dopaminergic and BDNF-driven cognitive enhancement; Selank provides GABAergic anxiolysis and enkephalin stabilization. Semax drives performance up; Selank prevents the anxiety that Semax's stimulatory profile can occasionally trigger in sensitive users. The combination produces the 'calm focus' state — cognitively engaged, not anxiously activated — that neither compound reliably produces alone for every user.

Practical sequencing: Selank intranasally in the morning (250-500 mcg) to establish the calm baseline and suppress any anxious activation before it develops. Semax intranasally at midday (300-900 mcg) for the cognitive peak when the BDNF-driven enhancement is most useful. This timing separation prevents Semax's stimulatory effects from disrupting sleep (no late-day dosing) while allowing the two compounds to complement rather than compete. Pre-mixed Semax + Selank intranasal formulations exist but sacrifice dosing flexibility — running them separately allows independent titration of each compound. No controlled study has evaluated the combination; mechanistic rationale and community consistency are the basis.

For users running healing peptide protocols with GLOW, KLOW, or the Wolverine Stack, adding Semax addresses the cognitive and neurological dimension of recovery. Post-injury recovery has a significant psychological component — anxiety about healing timescales, cognitive fog from pain or disrupted sleep, reduced motivation. Semax's BDNF upregulation and dopaminergic activation address all three. No pharmacological conflict exists between Semax and any healing stack compound.

For users running CJC-1295/Ipamorelin or Sermorelin for GH/anti-aging benefits, adding Semax addresses the cognitive enhancement dimension that GH secretagogues do not directly target. GH secretagogues support tissue anabolism and sleep quality; Semax supports hippocampal neuroplasticity and daytime cognitive performance. Non-overlapping axes, complementary outcomes.

Russian preclinical data and some community use center on BDNF protection in the context of alcohol exposure. Chronic alcohol reliably reduces hippocampal BDNF — a mechanism implicated in alcohol-related cognitive impairment and neurodegeneration. Semax's BDNF upregulation is mechanistically positioned to counter this. Some Russian clinical use addresses post-alcohol cognitive rehabilitation. Whether standard nootropic doses of Semax meaningfully offset the BDNF-depressing effects of alcohol is not established in controlled data, but the mechanism is coherent and the community uses it for this purpose.

Timeframe

What You May Notice

20-40 min (intranasal)

Onset of cognitive activation — increased mental clarity, reduced brain fog. More pronounced than Selank's anxiety-quieting onset. Some users describe it as 'the TV getting sharper.'

40-90 min

Peak acute effect window. Improved working memory, verbal fluency, and information processing speed. Dopaminergic motivation drive in some users.

2-4 hours

Sustained effect per dose (standard Semax). Gradual return to baseline. No crash or rebound. N-Acetyl Semax: reportedly 6-12 hours.

Days 1-5

Cumulative BDNF upregulation beginning. Baseline cognitive performance improving with consistent use.

Week 2-3

Full cumulative effect. Consistent reports of improved memory consolidation, faster learning, and enhanced creative problem-solving in this window.

Post-cycle

Return to pre-cycle baseline over days to weeks. No withdrawal. BDNF-mediated changes may take longer to normalize than Selank's receptor-level effects.

• Morning-only or AM/midday dosing: the most important factor. Late-day dosing ruins sleep; disrupted sleep eliminates any cognitive benefit the next day. Sleep quality IS cognitive performance.
• Lower starting doses: Semax has a meaningful dose-response curve for adverse effects. Starting at 250-400 mcg before escalating identifies the optimal dose for each individual. The range 600-900 mcg is where most users find the performance-to-adverse-effect balance.
• Pairing with Selank: prevents the anxious activation that can occur in some users at higher Semax doses or in higher-stress environments. The combination provides the cognitive benefit without the agitation risk.
• Consistent daily use during the cycle: BDNF upregulation is cumulative. Single doses produce acute effects; the full nootropic profile requires consistent daily administration over the cycle duration.
• No alcohol the evening before: alcohol depresses BDNF and serotonin, blunting Semax's effect the following day.

• Dosing after 2-3pm: the single most common failure mode. Late-day dopaminergic activation causes insomnia. Poor sleep eliminates cognitive benefits and creates a net deficit. Dose before 2pm. This is not negotiable for most users.
• Starting too high: Semax has a narrower therapeutic window for adverse effects than Selank. Starting at 1,000+ mcg on day one produces headache, nasal irritation, and sometimes agitation in first-time users. Start at 250-400 mcg and titrate.
• Using the 1% solution for nootropic purposes: 10x the concentration of the 0.1% nootropic formulation. Produces 10x the dose per drop. Community users should reconstitute at 0.1% (1 mg/mL). The 1% solution is a clinical stroke protocol concentration.
• Assuming N-Acetyl Semax is a straightforward upgrade: NA-Semax is a different compound with community-claimed advantages and no comparative clinical data. Some users find it superior; some prefer standard Semax. The choice involves real uncertainty that vendor marketing doesn't acknowledge.
• Conflating stroke evidence with nootropic evidence: the Gusev stroke trials are compelling. They were conducted at 15-30x the nootropic dose for acute ischemic stroke. They do not directly validate nootropic use. The most honest position: the mechanism is right, the dose-response at lower doses is plausible, and the direct evidence at nootropic doses is much thinner.

No physical dependence, no withdrawal syndrome. Return to pre-cycle cognitive baseline over days to weeks after stopping. Russian clinical protocols use 10-14 day courses. Community nootropic cycles of 10-14 days on, 7 days off are standard. Some users run 3-4 week cycles without reported tolerance issues. The cycling recommendation maintains receptor sensitivity and is a reasonable precaution.

Semax is available from Russian pharmacy formulations (Semax 0.1% and 1% nasal drops, manufactured by Peptogen LLC) — pharmaceutical-grade product with full quality assurance. Western research chemical vendors produce lyophilized powder for reconstitution. Quality requirements: HPLC purity 99%+ (Semax is sensitive to purity — truncated sequences confound the pharmacology); mass spectrometry confirming ~815 Da for standard Semax (distinguishes from NA-Semax at ~857 Da); endotoxin below 0.1 EU/mg for injectable use; batch-specific lot number. Pricing 2026: research vendor (HPLC + MS + endotoxin COA), 5 mg Semax: $45-65. N-Acetyl Semax: slightly higher, $50-75 for 5 mg. Russian pharmacy products (when accessible): often comparable cost per dose at equivalent concentrations.

Semax occupies a specific and well-defined community niche: high-performance cognitive enhancement without stimulant side effects. The community profile skews toward knowledge workers, students during intensive periods, and professionals managing high cognitive loads. The compound is consistently described as producing 'real cognitive benefit' rather than the placebo-adjacent effects of most nootropic supplements. The consistency of positive reports across independent community members — across years, across platforms, across dosing approaches — is one of the strongest category E evidence signals in this book.

The community's relationship with the stroke evidence is interesting. Most users are aware of the clinical trials and cite them approvingly — then use the compound at 1/20th of the studied dose for an entirely different purpose. This is not irrational. The mechanism is operating at nootropic doses (BDNF is going up at lower doses too), and the dose required for cognitive enhancement may genuinely be lower than the dose required for acute stroke intervention. But it means the community is operating substantially on faith in the mechanism plus their own experience rather than on direct evidence at their use case.

Intranasal: mild stinging in some users at application. The effect onset is more cognitively textured than Selank's anxiety-quieting profile. Users describe increased mental sharpness, faster thought processing, and improved verbal recall. The dopaminergic component produces a mild motivation drive — not stimulant energy, but cleaner engagement with tasks. Some users report enhanced focus under distracting conditions. At higher doses or in stimulant-sensitive individuals, this activation can tip into mild agitation or racing thoughts — the reason Selank pairing helps. The effect is more noticeable to neurotypical users than Selank's anxiolytic effect, because Selank primarily takes something away (anxiety), while Semax adds something (cognitive sharpness).

Myasoedov NF, et al. Development of Semax as a synthetic ACTH(4-10) analog for clinical use. Institute of Molecular Genetics RAS. [Original development series, 1980s-1990s]

Dolotov OV, Karpenko EA, Inozemtseva LS, et al. (2006). Semax, an analog of ACTH(4-7) with Pro-Gly-Pro, activates hippocampal BDNF and VEGF expression in rats. Brain Research, 1120(1), 130-137. PMID: 16996037. [THE foundational BDNF paper: single intranasal dose, BDNF mRNA +3x, protein +1.4x, TrkB phosphorylation +1.6x in hippocampus. Widely cited, basis for nootropic mechanism claims.]

Romanova GA, et al. (2006) [2]. Semax reduces ischemic infarct volume in rats following photoinduced prefrontal cortex ischemia after 6 days of intranasal administration. [Neuroprotection — stroke model; development institution]

Eremin KO, et al. (2005). Semax activates dopaminergic and serotonergic brain systems within 30 minutes of intranasal administration in rats. [Monoaminergic activation; development institution]

PMC11498467. (2024). Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. PubMed Central. [INDEPENDENT — different institution; confirms PGP tail is pharmacologically active, not just a stabilizing appendage; adds neuroprotective gene expression data]

Gusev EI, Skvortsova VI, et al. Multiple Russian clinical trials, 1990s-2000s. Semax in acute ischemic stroke: improved NIHSS, Barthel Index, modified Rankin Scale vs standard care or placebo; IL-10 upregulation, IL-8/CRP reduction. [Development institution provenance; multiple studies; no Western replication]

Russian clinical study (2018) [7]. 110 patients recovering from ischemic stroke. BDNF elevation with Semax treatment correlated with improved rehabilitation trajectory. [Human BDNF correlation — strongest human mechanistic data]

Russian study (1996). n=11 healthy subjects. 250-1,000 mcg Semax: improved attention and short-term memory (71% vs 41% baseline in follow-up memory test). [Only direct human nootropic evidence at community doses; tiny n; development institution]

Russian fMRI study (2018). n=24 healthy volunteers. Semax increased default mode network activity relative to placebo. [Neuroimaging evidence; healthy volunteers; Russian]

Kasian VS, et al. (2015-2016). PMID: 26847159. Genome-wide transcriptomic analysis of Semax effects: dopaminergic, serotonergic, and neurotrophin pathway gene modulation. [Development institution; broadest gene expression characterization]

Inozemtseva LS, et al. (2024). Antidepressant-like and antistress effects of ACTH(4-10) synthetic analogs Semax and Melanotan II in male rats with chronic unpredictable stress. European Journal of Neuropharmacology. [INDEPENDENT; 2024; antidepressant-like effects in CUS model; efficacy comparable to PGP fragment]

Russian Federation. List of Vital and Essential Drugs. Semax added 2011. Approved indications: ischemic stroke, TIA, cognitive disorders, optic nerve disease.

FDA. (2026, April 15-22). Removal of Semax (acetate and free base) from 503A Category 2. PCAC review July 24, 2026 for cerebral ischemia, migraine, and trigeminal neuralgia. Federal Register.

Well-suited for: knowledge workers seeking evidence-based cognitive enhancement without stimulant side effects; users pairing Semax + Selank for calm focus; anyone with interest in neuroprotection as a longevity/performance strategy; users recovering from neurological injury (post-concussion, post-stroke) with physician oversight; the user who has read the stroke literature and is rationally extrapolating the mechanism to a lower-dose nootropic application.

Extra caution for: athletes subject to WADA testing (S0 coverage uncertain — verify before use); individuals with history of psychosis, bipolar disorder, or stimulant sensitivity (dopaminergic activation warrants physician discussion); people prone to insomnia (timing discipline is essential); anyone planning to use 1% formulation concentrations outside of clinical supervision.

Not appropriate for: anyone expecting Semax to replicate its stroke trial outcomes at nootropic doses without clinical supervision; anyone using it for acute neurological emergency without medical oversight; oral administration at any dose.

If your primary goal is...

The better choice is...

Why

Anxiety reduction without sedation

Selank

GABAergic + enkephalin mechanism; designed for this

Cognitive enhancement / focus

Semax

BDNF + dopaminergic; stronger nootropic mechanism

Neuroprotection post-injury

Semax

Strongest clinical evidence is in neurological recovery

Calm + focused simultaneously

Semax + Selank

Complementary mechanisms; the combination is the answer

Sleep quality improvement

Selank

Anxiolytic; no insomnia risk; supports parasympathetic

Afternoon/evening use

Selank

Semax at these times risks insomnia

Minimal adverse effect concern

Selank

Slightly cleaner side effect profile at equivalent doses

Strongest clinical credentialing

Semax

Vital Medicines List + stroke trial data

• The stroke evidence validates nootropic use: the stroke trials show efficacy at 9,000-18,000 mcg/day for acute ischemic stroke. Community nootropic use is at 600-1,200 mcg/day for cognitive enhancement. Same mechanism, different doses, different application, different evidence quality. Citing stroke trials to justify nootropic use is citing evidence from a different regime.
• 'On the Vital Medicines List' means approved for any use: Russian Vital Medicines List status covers the registered indications. Off-label use — including nootropic use in healthy people — is not covered by the clinical evidence that generated the registration.
• N-Acetyl Semax is a proven upgrade: it is a community claim without comparative pharmacokinetic data. It may be superior for some users and worse for others. The vendor marketing overstates the evidence.
• Semax and Selank are interchangeable Russian nootropic peptides: they have different sequences, different mechanisms (ACTH-derived vs tuftsin-derived), different primary applications (nootropic vs anxiolytic), and different adverse effect profiles (insomnia risk with Semax; none with Selank). They are complementary, not interchangeable.

— End of Semax —

THE PEPTIDE BIBLE | Semax | For Research & Educational Purposes Only